Serum neopterin in workers exposed to inorganic dust containing free crystalline silicon dioxide

• Authors: Gospodinka Prakova , Pavlina Gidikova , Emil Slavov , Gergana Sandeva , Spaska Stanilova
• Languages of publication: EN

Abstracts

EN

The study was conducted among 92 male workers, divided into two groups depending on workplace and level of inorganic dust containing free crystalline SiO2 in the work environment, and 43 healthy workers without exposure to dust aerosols. The measured inhalable and respirable dust concentrations, as well as the concentration of free crystalline silica (FCS) in the respirable fraction were different for the two groups, but the percentage of free crystalline silica in the respirable fraction was almost identical. Significantly higher neopterin levels were found in workers exposed to dust, compared to the control group: 12.72 nmol/L and 6.32 nmol/L respectively (p<0.05). No significant difference was found between serum neopterin levels in both groups of the exposed workers. Among the groups with different length of service, a statistically higher neopterin level was evident only in the workers with length of service less than 10 years (p<0.05). The correlation analysis did not find a significant dependence of neopterin levels on the age of the studied workers or on the duration of smoking in packet years. The difference between neopterin levels in smokers and non-smokers was nonsignificant. The results obtained show that increased neopterin levels in the exposed workers are not influenced by individual features, duration and level of exposure to inorganic dust, but mostly by the presence of FCS in the respirable fraction.

Keywords

EN

Neopterin; Inorganic dust

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 1
• Pages: 104-109

Dates

published

1 - 3 - 2009

online

11 - 2 - 2009

Contributors

author

Gospodinka Prakova

• University Hospital, 6003, Stara Zagora, Bulgaria

author

Pavlina Gidikova

• Medical Faculty, Trakia University, 6003, Stara Zagora, Bulgaria

author

Emil Slavov

• Medical Faculty, Trakia University, 6003, Stara Zagora, Bulgaria

author

Gergana Sandeva

• Medical Faculty, Trakia University, 6003, Stara Zagora, Bulgaria

author

Spaska Stanilova

• Medical Faculty, Trakia University, 6003, Stara Zagora, Bulgaria

References

• [1] Petrova E., Manual for dust-associated occupational pulmonary diseases, MTSP, Working conditions fund, Sofia, 2004
• [2] Kostova V., Petkova V., Occupational diseases. Dust and allergic diseases, Ral Colober, Sofia, 2007
• [3] Krastev Z., Internal medicine, Sofia, 2006
• [4] Rimal B., Greenberg A., Rom W.N., Basic pathogenic mechanisms in silicosis: current understanding. Obstructive, occupational and environmental diseases, Curr. Opinion. Pulm. Med., 2005, 11, 169–173 http://dx.doi.org/10.1097/01.mcp.0000152998.11335.24[Crossref]
• [5] Brooke T., Churg M., Churg A., Mechanisms in the pathogenesis of asbestosis and silicosis, Am. J. Respir. Crit. Care Med., 1998, 157, 1666–1680
• [6] Kim K.A., Park C.Y., Lim Y., Lee K.H., Recent advances in particulate-induced pulmonary fibrosis; for the application of possible strategy experimentally and clinically, Current Drug Targets, 2000, 1, 297–307 http://dx.doi.org/10.2174/1389450003349146[Crossref]
• [7] Karnik A.B. et al., Immune response to exposure to occupational and environmental agents, ICMR Buletin, June–July, 2001, 31, No 6&7
• [8] Davis G.S., Holmes C.E, Pfeiffer L.M., Hemenway D.R., Lymphocytes, lymphokines, and silicosis, J. Environ. Pathol. Toxicol. Oncol., 2001, 20, Suppl. 1, 53–65
• [9] Davis G.S, Pfeiffer L.M., Hemenway D.R., Rincon M., Interleukin-12 is not essential for silicosis in mice, Part. Fibre Toxicol., 2006, 3, 2 http://dx.doi.org/10.1186/1743-8977-3-2[Crossref]
• [10] Pilette C., Ouadrhiri Y., Van Snick J., Renauld J-C., Staquet P., Vaerman J-P., et al., Oxidative burst in lipopolysaccharide-activated human alveolar macrophages is inhibited by interleukin-9, Eur. Respir. J., 2002, 20, 1198–1205 http://dx.doi.org/10.1183/09031936.02.00005402[Crossref]
• [11] Tiwari R.R., Biomarkers of silicosis: Potential candidates, IJOEM, 2005, 9, 103–106
• [12] Huaux F., Arras M., Tomasi D., Barbarin V., Monique Delos M., Coutelier J-P., et al., A Profibrotic Function of IL-12p40 in Experimental Pulmonary Fibrosis, J. Immunol., 2002, 169, 2653–2661 [Crossref]
• [13] Vanhée D., Gosset P., Boitelle A., Wallaert B., Tonnel A.B., Cytokines and cytokine network in silicosis and coal workers’ pneumoconiosis, Eur. Respir. J., 1995, 8, 834–842
• [14] Brown J., Pfau J., Holian A., Immunoglobulin and Lymphocyte Responses Following Silica Exposure in New Zealand Mixed Mice, Inhalation Toxicology, 2004, 16, 133–139 http://dx.doi.org/10.1080/08958370490270936[Crossref]
• [15] Borm P., Pamen N., Engelen J. and Buurman W.A., Spontaneous and stimulated release of tumour necrosis factor-a (TNF) from blood monocytes of miners with coal workers’ pneumoconiosis, Am. Rev. Respir. Dis., 1988, 138, 1589–1594 [Crossref]
• [16] Otsuki T. Tomokuni A., Sakaguchi H., Hyodoh F., Kusaka M., Ueki A., Reduced Expression of the Inhibitory Genes for Fas-mediated Apoptosis in Silicosis Patients, J. Occup. Health., 2000, 42, 163–168 http://dx.doi.org/10.1539/joh.42.163[Crossref]
• [17] Tomokuni A. Otsuki T., Isozaki Y., Kita S., Ueki H., Kusaka M., et al., Serum levels of soluble Fas ligand in patients with silicosis, Clin. Exp. Immunol., 1999, 118, 441–444 http://dx.doi.org/10.1046/j.1365-2249.1999.01083.x[Crossref]
• [18] Garn H., Friedetzky A., Kirchner A., Jäger R., Gemsa D., Experimental silicosis: a shift to a preferential IFN-g-based Th1 response in thoracic lymph nodes, Am. J. Physiol. Lung Cell Mol. Physiol., 2000, 278, 1221–1230
• [19] Piguet P.F., Is “tumor necrosis factor” the major effector of pulmonary fibrosis?, Eur. Cytokine Netw., 1990, 1, 257–258
• [20] Gossart S., Cambon C., Orfila C., Seguelas M.H., Lepert J.C., Rami J., et al., Reactive oxygen intermediates as regulators of TNF-alpha production in rat lung inflammation induced by silica, J. Immunol., 1996, 156(4), 1540–1548
• [21] Lassalle P., Gosset P., Aerts C., Fournier E., Lafitte J.J., Degreef J.M., et al., Abnormal secretion of interleukin-1 and tumor necrosis factor alpha by alveolar macrophages in coal worker’s pneumoconiosis: comparison between simple pneumoconiosis and progressive massive fibrosis, Exp. Lung. Res., 1990, 16(1), 73–80 http://dx.doi.org/10.3109/01902149009064700[Crossref]
• [22] Zhai R, Liu G, Ge X., Bao W., Wu C., Yang C., et al., Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), and their soluble receptors in coal workers’ pneumoconiosis, Respir. Med., 2002, 96(10), 829–834 http://dx.doi.org/10.1053/rmed.2002.1367[Crossref]
• [23] Gulumian G., Murray J., Nelson G., Darvin L., Valliathan V., Castranova V., et al., Biomarkers of silicosis, International EUROGIN-EAST conference, Vilnius, 2001.
• [24] Murr C., Fuith L.C., Widner B., Wirleitner B., Baier-Butterlich G., Fuchs D., Increased neopterin concentrations in patients with cancer: indicator of oxidative stress, Anticancer Res., 1999, 19, 1721–1728
• [25] Milstein S., Kapatos G., Levine R.A., Shane B., Chemistry and biology of pteridines and folates, Kluwer, Norwell, Massachusetts, 2002
• [26] Hoffmann G., Wirleitner B., Fuchs D., Potential role of immune system activation-associated production of neopterin derivates in humans, Inflamm. Res., 2003, 52, 313–321 http://dx.doi.org/10.1007/s00011-003-1181-9[Crossref]
• [27] Muller-Quernheim J., Zissel G., Schopf R., Vollmer E., Schlaak M., Differential diagnosis of berylliosis/sarcoidosis in a dental technician, Dtsch. Med. Wochenschr., 1996, 22, 1462–1466 http://dx.doi.org/10.1055/s-2008-1043169[Crossref]
• [28] Maier L.A., Kittle L.A., Mroz M.M., Newman L.S., Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease, Am. J. Ind. Med., 2003, 43, 592–601 http://dx.doi.org/10.1002/ajim.10227[Crossref]
• [29] Harris J., Bartelson B.B., Barker E., Balkissoon R., Kreiss K., Newman L.S., Serum neopterin in chronic beryllium disease, Am. J. Ind. Mwd., 1997, 32, 21–26 http://dx.doi.org/10.1002/(SICI)1097-0274(199707)32:1<21::AID-AJIM3>3.0.CO;2-U[Crossref]
• [30] Lacronic J., Auzeby A., Valeyre D., Traore B.M., Barbosa M.L., Soler P., et al., Urinary neopterin in pulmonary sarcoidosis. Relationship to biologic assessment of the disease, Am. Rev. Respir. Dis., 1989, 139, 1474–1478 [Crossref]
• [31] Tzouvelekis A., Kouliatsis G., Anevlavis S., Bouros D., Serum biomarkers in interstitial lung diseases, Respiratory Research, 2005, 6, 78 http://dx.doi.org/10.1186/1465-9921-6-78[Crossref]
• [32] Mota Pinto A., Todo Bom A., Vale Pereira S., Alves V., Santos Rosa, M., Elevated neopterin levels in non-allergic asthma, Pathophysiology, 2007, 14, 35–39 http://dx.doi.org/10.1016/j.pathophys.2006.10.001[Crossref]
• [33] Saito M., Chichara J., Mouri T., Kurach D., Yamamoto T., Nakajima S., Elevated local production of neopterin from alveolar macrophages from patients with interstitial lung diseases, Gen. Pharmacol., 1996, 27, 483–486 [Crossref]
• [34] Harald S., Christian M., Elmar G., Peter M., Diether S., Dietmar F., Factors influencing serum neopterin concentrations in a population of blood donors, Clinical Chemistry, 2002, 48, 643–645
• [35] Backe E., Gartzke J., Plitzko S., Effektmonitoring bei Schweiβrauchbelastung - Analyse ausgewählter immunologischer Parameter im Blut von Schweiβern und einer Kontrollgruppe, Forschung Projekt F 2021, Bundesanstalt für Arbeitsschutz und Arbeitsmedizin, 2006

Identifiers

DOI

10.2478/s11536-008-0084-0